On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
Egetis is a commercial-stage pharmaceutical company focused on developing and delivering innovative therapies for patients with rare diseases with significant unmet medical need. Its lead product, EMCITATE® (tiratricol), is the first and only approved treatment for MCT8 deficiency, with marketing authorizations in the European Union and in the United States. Headquartered in Stockholm, Sweden, Egetis has operations in the U.S. and Europe. The company is listed on Nasdaq Stockholm.
Vinge’s team mainly consists of Dain Hård Nevonen, Izabella Barisa, Elias Kröger and Samuel Rapp.
